LSD1 Inhibition to Preserve CAR-T Memory Phenotype
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing CAR-T cell therapies face challenges with T-cell exhaustion and loss of memory phenotype, leading to relapse in cancer treatment, necessitating alternative approaches to enhance durability and efficacy.
Innovation Solution
Incorporating a lysine-specific demethylase 1 (LSD1) inhibitor to treat immune effector cells, such as CAR-T cells, to inhibit the transition from memory to differentiated phenotype and prevent exhaustion, thereby enhancing their therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CAR-T cells are used to treat cancer, then antitumor activity is improved, but T-cell exhaustion and loss of memory phenotype occur leading to relapse
Solution Approach 1:
The patent applies parameter changes by using LSD1 inhibitors to modify the epigenetic state of CAR-T cells. The inhibitor changes the methylation status of histone H3 at specific sites (H3K4me2), thereby altering the transcriptional profile of T cells to maintain memory phenotype and prevent exhaustion, directly addressing the contradiction between antitumor activity and therapy durability
Solution Approach 2:
The LSD1 inhibitor acts as an intermediary substance that mediates between the CAR-T cells and the tumor microenvironment. By binding to LSD1 and preventing its demethylase activity, the inhibitor creates a protective epigenetic state in T cells that maintains their memory phenotype and prevents exhaustion during tumor antigen exposure
2Reliability
If PRDM1 knockout is implemented in CAR-T cells, then exhaustion is reduced, but a new drug product approval is required which complicates current therapies
Solution Approach 1:
The patent replaces the genetic modification approach (PRDM1 knockout) with a pharmacological approach (LSD1 inhibitor). Instead of permanently altering the T-cell genome through CRISPR or viral transduction, the invention uses a small molecule inhibitor that temporarily blocks LSD1 activity, thereby maintaining memory phenotype without requiring complex genetic engineering or new drug product approvals
Solution Approach 2:
The invention changes the approach from genetic modification to epigenetic modulation. By using LSD1 inhibitors to alter histone methylation status dynamically rather than permanently deleting PRDM1, the system achieves similar functional outcomes (maintained memory phenotype) with simpler manufacturing and regulatory pathways
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of LSD1 inhibitors maintains the memory phenotype of CAR-T cells, improving their durability and antitumor activity, reducing exhaustion, and enhancing clinical efficacy in cancer treatment.
Implementation Method 1
The Blimp1 (PRDM1) protein recruits to chromatin lysine-specific demethylase 1 (LSD1) which in turn effects epigenetic changes in histone and DNA methylation states to alter the transcriptional profile of lymphocytes. Inhibition of LSD1 with a small molecule inhibitor provides an alternative to the genetic knock-down of PRDM1.
Implementation Method 2
LSD1 inhibitors that affect the ability of LSD1 and its complex of proteins and to bind to both the GFI1 and Blimp1 family of transcriptions factors are expected to have advantages over LSD1 inhibitors which bind and inhibit LSD1 alone.
Data Source
AI summary
Provided herein is the use of LSD1 inhibitors, in particular bomedemstat, in connection with use and manufacture of immune effector cells such as NK cells and T cells engineered to express a chimeric antigen receptor (CAR), to treat a subject having a disease, associated with expression of a tumor antigen.